Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds
Translational Molecular Imaging in Oncologic Therapy Monitoring

Junior Clinical Cooperation Unit Translational Molecular Imaging in Oncologic Therapy Monitoring

PD Dr. Freba Grawe

Metastasized cancer patient in FDG-PET.
© dkfz.de

Management of cancer patients can be challenging, especially when it comes to selecting the most suitable treatment that promises the best success with minimal side effects. To monitor treatment success, regular follow-up checks are conducted. Molecular imaging plays a crucial role in this process. Radioactive substances are administered to the patient to visualize biological processes non-invasively using Positron Emission Tomography (PET). The combination of PET with Computed Tomography (PET/CT) or Magnetic Resonance Imaging (PET/MRI) allows us to capture functional and morphological information simultaneously.

Our goal is to harness the capabilities of molecular imaging, especially PET, to translate research results into clinical practice. In our clinical cooperation unit, experts from various disciplines, including nuclear medicine physicians, radiologists, radiopharmacists, and medical physicists work together on the development and establishment of innovative PET tracers using cutting-edge technology such as the long-axial field of view PET/CT, PET/MRI, and photon-counting CT to advance personalized oncology. In doing so, we aim to improve the early detection of cancer and precise prediction of therapy success for our patients. Our work represents a significant step toward precision medicine for oncology patients.

Contact

PD Dr. Freba Grawe
Translational Molecular Imaging in Oncologic Therapy Monitoring (E310)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel: +49 1737245988

Selected Publications

  • Grawe, Freba et al. “Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients.” European radiology, 10.1007/s00330-023-10083-7. 25 Aug. 2023, doi:10.1007/s00330-023-10083-7
  • Grawe, Freba et al. “Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs.” Cancer imaging : the official publication of the International Cancer Imaging Society vol. 23,1 41. 25 Apr. 2023, doi:10.1186/s40644-023-00556-9
  • Grawe, Freba et al. “Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients.” European radiology vol. 33,5 (2023): 3416-3424. doi:10.1007/s00330-023-09518-y
  • Fabritius, M P et al. “Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors.” Cancer imaging : the official publication of the International Cancer Imaging Society
to top
powered by webEdition CMS